Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 1
2022 4
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
Post-remission cytopenia management in patients with AML treated with venetoclax in combination with hypomethylating agents: Pre- versus post-VIALE-A real-world experience from a predominantly US community setting.
Vachhani P, Ma E, Xu T, Montez M, Worth S, Yellow-Duke A, Cheng WH, Werner ME, Abbas J, Donnellan W. Vachhani P, et al. Among authors: worth s. Cancer Med. 2023 Sep;12(17):17914-17923. doi: 10.1002/cam4.6430. Epub 2023 Aug 11. Cancer Med. 2023. PMID: 37568276 Free PMC article.
Dismal survival outcomes of patients with acute myeloid leukemia after failure of venetoclax with hypomethylating agents.
Zainaldin C, Arora S, Bathini S, Gupta U, Pandya V, Bae S, Worth S, Bachiashvili K, Bhatia R, Godby K, Jamy O, Rangaraju S, Diamond B, Oliver JD, Salzman D, Di Stasi A, Vachhani P. Zainaldin C, et al. Among authors: worth s. Leuk Lymphoma. 2022 Dec;63(13):3245-3248. doi: 10.1080/10428194.2022.2113530. Epub 2022 Sep 15. Leuk Lymphoma. 2022. PMID: 36107006 No abstract available.
Utility of end of induction bone marrow biopsy and survival outcomes in acute promyelocytic leukemia treated with fixed-dose induction regimen.
Dunn-Valadez S, Bathini S, Purdy KE, Bachiashvili K, Bhatia R, Jamy O, Rangaraju S, Mehta A, Godby K, Goyal G, Worth S, Oliver JD, Mikhail FM, Choi JK, Morlote D, Reddy VB, Vachhani P. Dunn-Valadez S, et al. Among authors: worth s. Leuk Lymphoma. 2023 Oct;64(10):1673-1680. doi: 10.1080/10428194.2023.2234529. Epub 2023 Jul 26. Leuk Lymphoma. 2023. PMID: 37493540
Tumor lysis syndrome and infectious complications during treatment with venetoclax combined with azacitidine or decitabine in patients with acute myeloid leukemia.
Arora S, Zainaldin C, Bathini S, Gupta U, Worth S, Bachiashvili K, Bhatia R, Godby K, Jamy O, Rangaraju S, Diamond B, Oliver JD, Salzman D, Di Stasi A, Vachhani P. Arora S, et al. Among authors: worth s. Leuk Res. 2022 Jun;117:106844. doi: 10.1016/j.leukres.2022.106844. Epub 2022 Apr 25. Leuk Res. 2022. PMID: 35487134